Literature DB >> 24925233

The 20-year effort to reduce access to mammography screening: historical facts dispute a commentary in Cancer.

Daniel B Kopans1, Matthew L Webb, Blake Cady.   

Abstract

Mammography screening fulfills all requirements for an effective screening test. It detects many cancers earlier when they are at a smaller size and earlier stage, and it has been demonstrated that this reduces breast cancer deaths in randomized controlled trials. When screening is introduced into the population, the death rate from breast cancer declines. Nevertheless, scientifically unsupported arguments that appear in the medical literature are passed on to the public and continue to confuse women and physicians regarding the value of screening. Methodologically flawed challenges to mammography have been almost continuous since the 1990s. And, as each challenge has been invalidated, a new, specious challenge has been raised. The authors of this report address the long history of misinformation that has developed in the effort to reduce access to screening, and they address the issues raised by commentators concerning their recent publication in this journal.
© 2014 American Cancer Society.

Entities:  

Keywords:  breast cancer; cancer; mammography; mortality; screening

Mesh:

Year:  2014        PMID: 24925233     DOI: 10.1002/cncr.28791

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Controversies on Mammography Screening in the World and Bahceşehir Population-Based Organized Mammography Screening Project in Turkey.

Authors:  Vahit Özmen
Journal:  J Breast Health       Date:  2015-10-01

2.  How Did CNBSS Influence Guidelines for So Long and What Can That Teach Us?

Authors:  Shushiela Appavoo
Journal:  Curr Oncol       Date:  2022-05-30       Impact factor: 3.109

3.  At what age should screening mammography be recommended for Asian women?

Authors:  Junko Tsuchida; Masayuki Nagahashi; Omar M Rashid; Kazuaki Takabe; Toshifumi Wakai
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.